Publications by authors named "Howard Edelstein"

Claim this Profile
P
Primary nasal Kaposi Sarcoma in well-controlled HIV-positive patient with normal CD4 count associated with long-term nasal steroid use.
Kyaw Zin Htet, Michael Waul, Howard Edelstein, Stanley Mui, Sarah Cherny

Int J STD AIDS· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
Kevin Robertson, Paul Maruff, Lisa L Ross, David Wohl, Catherine B Small, Howard Edelstein

J Neurovirol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical Trials.
Jun Yong Choi, Somnuek Sungkanuparph, Thanomsak Anekthananon, Paul Sax, Edwin DeJesus, Howard Edelstein

Infect Chemother· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection.
Trevor A Crowell, Kelly A Gebo, Joel N Blankson, P Todd Korthuis, Baligh R Yehia, Howard Edelstein

J Infect Dis· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.
David A Wohl, Laveeza Bhatti, Catherine B Small, Howard Edelstein, Henry H Zhao

PLoS One· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
Princy Kumar, Edwin DeJesus, Gregory Huhn, Louis Sloan, Catherine Butkus Small, Howard Edelstein

BMC Infect Dis· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of HIV in outpatients with schizophrenia, schizoaffective disorder and bipolar disease at two county clinics.
Kaitlyn Murphy, Howard Edelstein, Lance Smith, Kathleen Clanon, Beth Schweitzer

Community Ment Health J· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Internal warts and associated anal diseases are common in patients attending a county HIV clinic.
Howard Edelstein, J Trees Ritter

J Acquir Immune Defic Syndr· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Failure of treatment of tuberculous adenitis due to an unexpected drug interaction with rifabutin and efavirenz.
Howard E Edelstein, Yolanda Cuadros

AIDS· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis